Stocktoria
ACCENDRA HEALTH INC/VA/ ACH
NYSE · stock · Wholesale-Medical, Dental & Hospital Equipment & Supplies · website · IPO 1980-03-17
ACCENDRA HEALTH INC/VA/ financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8B | $2.7B | $2.6B | $10.0B | $9.8B | $8.5B | $9.2B | $9.4B | $9.3B | $9.7B |
| Gross profit | — | $2.2B | $2.1B | $1.8B | $1.5B | $1.3B | $1.1B | $1.1B | $1.2B | $1.2B |
| R&D expense | — | $13.0M | $13.0M | $12.0M | $12.1M | — | — | — | — | — |
| SG&A expense | $1.1B | $1.1B | $1.0B | $1.6B | $1.1B | $1.0B | $1.0B | $952.9M | $1.0B | $970.4M |
| Operating income | $27.5M | -$217.7M | $133.2M | $142.9M | $368.5M | $204.1M | $73.2M | -$352.3M | $89.3M | $199.6M |
| Interest expense | $107.2M | $107.6M | $116.8M | $128.9M | $48.1M | $83.4M | $98.1M | $71.0M | $31.8M | $27.1M |
| Income tax | $729,000 | $20.9M | $6.4M | -$11.5M | $55.2M | $21.8M | -$6.1M | -$32.4M | -$15.3M | $63.8M |
| Net income | -$1.1B | -$362.7M | -$41.3M | $22.4M | $221.6M | $29.9M | -$62.4M | -$437.0M | $72.8M | $108.8M |
| EPS (diluted) | $-14.31 | $-4.73 | $-0.53 | $0.29 | $2.94 | $0.47 | $-1.03 | — | — | $1.76 |
| Operating cash flow | -$101.8M | $161.5M | $740.7M | $325.0M | $124.2M | $339.2M | $166.1M | $115.6M | $56.8M | $187.7M |
| Free cash flow | -$292.7M | -$8.8M | $568.3M | $166.9M | $83.2M | $288.8M | $123.7M | $70.7M | $22.2M | $167.4M |
| Cash & equivalents | $282.0M | $27.6M | $243.0M | $69.5M | $55.7M | $83.1M | $67.0M | $66.3M | $104.5M | $185.5M |
| Inventory | $74.4M | $67.6M | $1.1B | $1.3B | $1.5B | $1.2B | $1.1B | $1.3B | $990.2M | $916.3M |
| Total assets | $2.5B | $4.7B | $5.1B | $5.4B | $3.5B | $3.3B | $3.6B | $3.8B | $3.4B | $2.7B |
| Total liabilities | $2.9B | $4.1B | $4.2B | $4.4B | $2.6B | $2.6B | $3.2B | $3.3B | $2.4B | $1.8B |
| Shareholders' equity | -$461.0M | $586.4M | $945.3M | $966.7M | $938.5M | $712.1M | $462.2M | $518.4M | $1.0B | $960.0M |
Growth · year-over-year · Revenue CAGR -13.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +3.1% | +5.0% | -74.4% | +1.7% | +15.4% | -7.9% | -2.2% | +1.1% | -4.2% | -0.5% |
| Net income growth | — | — | -284.5% | -89.9% | +641.8% | — | — | -700.3% | -33.1% | +5.2% |
| EPS growth | — | — | -282.8% | -90.1% | +525.5% | — | — | — | — | +6.7% |
| Free cash flow growth | — | -101.5% | +240.5% | +100.6% | -71.2% | +133.5% | +74.9% | +219.1% | -86.8% | -33.0% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.